172 related articles for article (PubMed ID: 36192243)
21. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
[TBL] [Abstract][Full Text] [Related]
22. Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
Liu Z; Zhang T; Ma Z; Zheng S; Chen J; Wu Z; Zheng X; Li X; Liu Z
Am J Clin Oncol; 2020 Apr; 43(4):288-297. PubMed ID: 31972568
[TBL] [Abstract][Full Text] [Related]
23. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
[TBL] [Abstract][Full Text] [Related]
25. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis.
Rizzo A; Merler S; Sorgentoni G; Oderda M; Mollica V; Gadaleta-Caldarola G; Santoni M; Massari F
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1237-1243. PubMed ID: 34407702
[No Abstract] [Full Text] [Related]
26. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.
Berruti A; Bracarda S; Caffo O; Cortesi E; D'Angelillo R; Del Re M; Facchini G; Pappagallo G; Procopio G; Sabbatini R; Santini D
Cancer Treat Rev; 2023 Apr; 115():102525. PubMed ID: 36822009
[TBL] [Abstract][Full Text] [Related]
27. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
Wang L; Paller C; Hong H; Rosman L; De Felice A; Brawley O; Alexander GC
J Natl Cancer Inst; 2022 Feb; 114(2):191-202. PubMed ID: 33830214
[TBL] [Abstract][Full Text] [Related]
29. Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
Rodriguez-Vida A; Rodríguez-Alonso A; Useros-Rodríguez E; Lopez-Campos F; Amor-Carro O; Arribas-Ruiz A; Martinez-Torres J; Roca-Pardiñas J; Quesada-García A; Muñoz-Del-Toro JR; Juárez-Soto Á
Clin Genitourin Cancer; 2022 Apr; 20(2):197.e1-197.e10. PubMed ID: 34920959
[TBL] [Abstract][Full Text] [Related]
30. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao B; Kim M; Reizine NM; Moreira DM
Eur Urol Oncol; 2023 Jun; 6(3):237-250. PubMed ID: 36682938
[TBL] [Abstract][Full Text] [Related]
31. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
32. Current treatment of non-metastatic castration-refractory prostate cancer.
Büchler T
Klin Onkol; 2021; 34(3):185-191. PubMed ID: 34362254
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
Morgans AK; Shore N; Cope D; McNatty A; Moslehi J; Gomella L; Sartor O
Urol Oncol; 2021 Jan; 39(1):52-62. PubMed ID: 32958445
[TBL] [Abstract][Full Text] [Related]
34. Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use.
Yang CK; Cha TL; Chang YH; Huang SP; Lin JT; Wang SS; Huang CY; Pang ST
J Formos Med Assoc; 2023 Apr; 122(4):299-308. PubMed ID: 36797129
[TBL] [Abstract][Full Text] [Related]
35. Non-metastatic castration-resistant prostate cancer: management recommendations.
Alcaraz Asensio A; Alvarez Ossorio JL; Cozar Olmo JM; Chantada Abal V; Juarez Soto A; Linares Espinos E; Moreno Jimenez J; Muñoz Rodriguez J; Perez Fentes D; Plata Bello A; Rodrigo Aliaga M; Unda Urzaiz M; Vilaseca A
Actas Urol Esp (Engl Ed); 2022 May; 46(4):193-213. PubMed ID: 35305957
[TBL] [Abstract][Full Text] [Related]
36. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
37. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile.
Mori K; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Grossmann NC; Rajwa P; Ploussard G; Briganti A; Kimura T; Egawa S; Papalia R; Carrion DM; Fiori C; Shariat SF; Esperto F; Pradere B
Minerva Urol Nephrol; 2022 Jun; 74(3):292-301. PubMed ID: 34308608
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
[TBL] [Abstract][Full Text] [Related]
40. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]